Shukui Qin
- Gastroenterology top 1%
- Hepatology top 1%
- Hepatocellular Carcinoma Treatment and Prognosis 18
- Oncology top 1%
- Colorectal Cancer Treatments and Studies 22
- Pancreatic and Hepatic Oncology Research 13
- Cancer Immunotherapy and Biomarkers 13
- Peptidase Inhibition and Analysis 9
-
- Gastric Cancer Management and Outcomes 24
- Lung Cancer Treatments and Mutations 18
-
- Cholangiocarcinoma and Gallbladder Cancer Studies 21
- Co-authors
- Jianming XuHyun Cheol ChungYuxian BaiJosep TaberneroEric Van CutsemYelena Y. JanjigianPooja BhagiaKohei Shitara
- Cited by
- GastroenterologyHepatologyOncology
- Partner nations
- ChinaUnited StatesSouth Korea
In The Last Decade
Shukui Qin
82 papers receiving 3.0k citations
Hit Papers
Peers
Comparison fields: 5 of 91
- Gastroenterology 396
- Hepatology 544
- Oncology 1.9k
- Pulmonary and Respiratory Medicine 1.5k
- Pathology and Forensic Medicine 461
Countries citing papers authored by Shukui Qin
This map shows the geographic impact of Shukui Qin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Shukui Qin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Shukui Qin more than expected).
Fields of papers citing papers by Shukui Qin
This network shows the impact of papers produced by Shukui Qin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Shukui Qin. The network helps show where Shukui Qin may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Shukui Qin, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 0 | |
| 2 | 2025 | 0 | |
| 3 | 2024 | 0 | |
| 4 | 2024 | 0 | |
| 5 | 2024 | 5 | |
| 6 | 2024 | 1 | |
| 7 | Nivolumab (NIVO) plus ipilimumab (IPI) vs lenvatinib (LEN) or sorafenib (SOR) as first-line treatment for unresectable hepatocellular carcinoma (uHCC): First results from CheckMate 9DW.breakdown → | 2024 | 75 |
| 8 | 2024 | 0 | |
| 9 | 2024 | 30 | |
| 10 | 2023 | 1 | |
| 11 | 2023 | 0 | |
| 12 | 2022 | 15 | |
| 13 | 2021 | 4 | |
| 14 | 2021 | 38 | |
| 15 | The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancerbreakdown → | 2021 | 449 |
| 16 | 2021 | 2 | |
| 17 | 2020 | 3 | |
| 18 | 2020 | 26 | |
| 19 | 2016 | 72 | |
| 20 | Status and progress of basic researches of elemene injection for anti-tumor. | 2010 | 12 |
About Shukui Qin
Shukui Qin is a scholar working on Hepatology, Oncology and Pulmonary and Respiratory Medicine, having authored 95 papers that have together received 3.1k indexed citations. Recurring topics across this work include Gastric Cancer Management and Outcomes (24 papers), Colorectal Cancer Treatments and Studies (22 papers), Cholangiocarcinoma and Gallbladder Cancer Studies (21 papers), Lung Cancer Treatments and Mutations (18 papers), Hepatocellular Carcinoma Treatment and Prognosis (18 papers), Pancreatic and Hepatic Oncology Research (13 papers), Cancer Immunotherapy and Biomarkers (13 papers) and Peptidase Inhibition and Analysis (9 papers). The work is most often cited by research in Gastroenterology (396 citations), Hepatology (544 citations) and Oncology (1.9k citations). Shukui Qin has collaborated with scholars based in China, United States and South Korea. Frequent co-authors include Jianming Xu, Hyun Cheol Chung, Yuxian Bai, Josep Tabernero, Eric Van Cutsem, Yelena Y. Janjigian, Pooja Bhagia, Kohei Shitara, Akihito Kawazoe and Sara Lonardi. Their work appears in journals such as Nature, The Lancet and Journal of Clinical Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.